Pedersen L M, Terslev L, SŁrensen P G, Stokholm K H
Department of Oncology and Hematology, Roskilde County Hospital, DK-Roskilde Denmark.
Med Oncol. 2000 May;17(2):117-22. doi: 10.1007/BF02796206.
Transcapillary escape rate of albumin was determined in 22 patients with different malignancies. In addition, urinary albumin excretion rate was measured in 24-h urine samples using a sensitive immunoassay. Increased urinary albumin excretion was defined as >/=20 microg/min according to conventional standards. Renal glomerular filtration and tubular function was estimated by 51Cr-EDTA plasma clearance and urinary beta 2-microglobulin, respectively. Median urinary albumin excretion rate was 15.0 microg/min (range 6-510 microg/min) and the frequency of increased urinary albumin excretion was 41%. This agrees with other studies showing increased albuminuria in several types of malignant diseases. Patients with advanced disease (tumour, node, metastasis (TNM) stage II-IV) had a significantly higher urinary albumin excretion rate than patients with localized disease (TNM stage I). Serum creatinine, glomerular filtration rate and urinary beta 2-microglobulin were all within normal limits. Median transcapillary escape rate of albumin was 5.5 %/h (range 2-8 %/h) and this level is comparable with values in healthy subjects. There was no significant difference in transcapillary escape rate between patients with elevated urinary albumin excretion and the normoalbuminuric group. Median value of the absolut outflux of albumin was 10.6 g/h with similar levels in patients with increased urinary albumin excretion and patients with normoalbuminuria. Our results indicate a high prevalence of minor glomerular dysfunction with a slightly elevated urinary albumin excretion in patients with malignancies. The normal endothelial function, as estimated by the transcapillary escape rate of albumin, suggests an overall unaffected capillary permeability and increased urinary albumin loss appears to be an isolated renal phenomenon in cancer patients.
在22例患有不同恶性肿瘤的患者中测定了白蛋白的跨毛细血管逃逸率。此外,使用灵敏的免疫测定法在24小时尿液样本中测量尿白蛋白排泄率。根据传统标准,尿白蛋白排泄增加定义为≥20微克/分钟。分别通过51Cr-EDTA血浆清除率和尿β2-微球蛋白评估肾小球滤过和肾小管功能。尿白蛋白排泄率中位数为15.0微克/分钟(范围6 - 510微克/分钟),尿白蛋白排泄增加的频率为41%。这与其他显示几种恶性疾病中蛋白尿增加的研究结果一致。患有晚期疾病(肿瘤、淋巴结、转移(TNM)分期II - IV期)的患者尿白蛋白排泄率显著高于患有局限性疾病(TNM分期I期)的患者。血清肌酐、肾小球滤过率和尿β2-微球蛋白均在正常范围内。白蛋白的跨毛细血管逃逸率中位数为5.5%/小时(范围2 - 8%/小时),该水平与健康受试者的值相当。尿白蛋白排泄增加的患者与正常白蛋白尿组之间的跨毛细血管逃逸率无显著差异。白蛋白绝对流出量的中位数为10.6克/小时,尿白蛋白排泄增加的患者和正常白蛋白尿患者的水平相似。我们的结果表明,恶性肿瘤患者中轻度肾小球功能障碍患病率较高,尿白蛋白排泄略有升高。通过白蛋白跨毛细血管逃逸率估计的正常内皮功能表明毛细血管通透性总体未受影响,尿白蛋白丢失增加似乎是癌症患者中一种孤立的肾脏现象。